Boston-based Acetylon Pharmaceuticals said today it has formed a new alliance with the Leukemia & Lymphoma Society. Under the deal, the nonprofit research foundation will contribute as much as $4.85 million to help Acetylon run a Phase I/II clinical trial program for an experimental drug against multiple myeloma. Acetylon’s oral drug, ACY-1215, is a histone deacetylase (HDAC) inhibitor. The company, founded on discoveries at Dana-Farber Cancer Institute and Harvard University, raised about $12 million in an equity financing in February.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
